ADARx Pharmaceuticals Inc. (ADRX)
ADRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ADRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0001802369 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $570.6M cash. | Report 2026-09-30 |
| Shares outstanding | 111,193,446 (2026-11-06). | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-09-28 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $33.3M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $2.2M | -$28.1M | Not filed | $570.6M | $815K | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2026-06-30 | Not filed | -$25.8M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2026-03-31 | Not filed | -$22.7M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-09-30 | $1.6M | -$17.9M | Not filed | $59.2M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-06-30 | Not filed | -$18.1M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-03-31 | Not filed | -$15.6M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2026-09-28 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 51 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +7.3% |
| 1 month | -19.8% |
| 3 months | Not enough price history |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -31.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PGEN | Precigen Inc. | $4.30 | -5.29% | $1.5B |
| QURE | uniQure N.V. | $21.88 | -8.11% | $1.5B |
| SLS | SELLAS Life Sciences Group Inc. | $7.47 | -4.96% | $1.5B |
| NRIX | Nurix Therapeutics Inc. | $14.73 | -4.84% | $1.6B |
| ANIP | ANI Pharmaceuticals Inc. | $70.89 | -0.77% | $1.6B |
| RARE | Ultragenyx Pharmaceutical Inc. | $15.90 | -1.12% | $1.6B |
| SRPT | Sarepta Therapeutics Inc. Common Stock (DE) | $15.13 | -5.85% | $1.6B |
| KRSA | Korsana Biosciences Inc. | $32.68 | +3.25% | $1.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier